| Title |
Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma
|
|---|---|
| Published in |
OncoTargets and therapy, November 2015
|
| DOI | 10.2147/ott.s92473 |
| Pubmed ID | |
| Authors |
Victor Ho-Fun Lee, Dennis KC Leung, Mai-Yee Luk, Chi-Chung Tong, Martin WM Law, Sherry CY Ng, Ka-Kin Wong, Ronnie TP Poon, Dora LW Kwong, To-Wai Leung |
| Abstract |
Advanced inoperable hepatocellular carcinoma (HCC) conferring a grave prognosis may benefit from yttrium-90 ((90)Y) radioembolization. Thirty patients with advanced inoperable HCC including those with any lesion >8 cm in maximal diameter or multiple bi-lobar lesions (totally more than five lesions), or portal vein thrombosis treated with radioembolization were reviewed. Treatment efficacy and safety were evaluated. Univariate and multivariate analyses were performed for identifying potential prognostic factors. After a median follow-up of 18.3 months, the response rate was 30.0%, and the disease control rate was 50.0%. Median overall progression-free survival (PFS) and overall survival (OS) were 3.3 months and 13.2 months, respectively. Longer median PFS was noted in those who had transarterial chemoembolization before radioembolization (7.3 months vs 3.1 months; P=0.021) and duration of alfafeto protein (AFP) response ≥6 months (11.8 months vs 3.0 months; P<0.001). Longer median OS was also revealed in those without portal vein thrombosis (17.1 months vs 4.4 months; P=0.015) and those whose duration of AFP response was ≥6 months (21.2 months vs 8.6 months; P=0.001). Seventeen patients (56.7%) developed treatment-related complications including five (16.7%) grade 3 events. Multivariate analysis revealed that treatment responders (P=0.001) and duration of AFP response ≥6 months (P=0.006) were prognostic of PFS, whereas the absence of portal vein invasion (P=0.025), treatment responders (P=0.010), and duration of AFP response ≥6 months (P=0.001) were prognostic of OS. (90)Y radioembolization is an alternative treatment with a promising outcome for poor-risk advanced inoperable HCC. |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| France | 1 | 3% |
| Unknown | 34 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 19% |
| Student > Bachelor | 5 | 14% |
| Researcher | 4 | 11% |
| Other | 3 | 8% |
| Student > Ph. D. Student | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 10 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 61% |
| Agricultural and Biological Sciences | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Unknown | 12 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 November 2015.
All research outputs
#20,297,343
of 22,835,198 outputs
Outputs from OncoTargets and therapy
#1,970
of 2,933 outputs
Outputs of similar age
#238,437
of 284,454 outputs
Outputs of similar age from OncoTargets and therapy
#70
of 104 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,933 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,454 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 104 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.